Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The company's President and CEO, Jack Khattar, will engage in a virtual fireside chat on Thursday, September 26, 2024, at 8:40 a.m. ET.
Interested parties can access a live webcast of the presentation through a provided link or by visiting the Events & Presentations section in the Investor Relations area of the company's website at www.supernus.com. An archived replay of the webcast will remain available on the company's website for 60 days following the conference.
Supernus Pharmaceuticals (Nasdaq: SUPN), un'azienda biofarmaceutica specializzata in malattie del sistema nervoso centrale (CNS), ha annunciato la sua partecipazione al 4° Summit Annuale sui Nuovi Meccanismi in Neuropsichiatria di TD Cowen. Il presidente e CEO dell'azienda, Jack Khattar, parteciperà a un chat informale virtuale il giovedì 26 settembre 2024, alle 8:40 a.m. ET.
Le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso un link fornito o visitando la sezione Eventi & Presentazioni nell'area Relazioni con gli Investitori del sito web dell'azienda all'indirizzo www.supernus.com. Una registrazione archiviata del webcast sarà disponibile sul sito dell'azienda per 60 giorni dopo la conferenza.
Supernus Pharmaceuticals (Nasdaq: SUPN), una compañía biofarmacéutica especializada en enfermedades del sistema nervioso central (CNS), ha anunciado su participación en el 4º Summit Anual sobre Nuevos Mecanismos en Neuropsiquiatría de TD Cowen. El presidente y CEO de la compañía, Jack Khattar, participará en un chat virtual informal el jueves 26 de septiembre de 2024, a las 8:40 a.m. ET.
Las partes interesadas pueden acceder a un webcast en vivo de la presentación a través de un enlace proporcionado o visitando la sección de Eventos y Presentaciones en el área de Relaciones con Inversores del sitio web de la compañía en www.supernus.com. Una reproducción archivada del webcast estará disponible en el sitio web de la compañía durante 60 días después de la conferencia.
Supernus Pharmaceuticals (Nasdaq: SUPN)는 중추신경계(CNS) 질환을 전문으로 하는 생물의약품 회사로, TD Cowen 제4회 신경정신의학의 새로운 메커니즘 정상회의에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Jack Khattar는 2024년 9월 26일 목요일 오전 8시 40분 ET에 가상 대화에 참여할 예정입니다.
관심이 있는 분들은 제공된 링크를 통해 발표의 실시간 웹캐스트에 접근하거나 회사 웹사이트의 투자자 관계 섹션 내 이벤트 및 발표 섹션을 방문하여 www.supernus.com에서 확인할 수 있습니다. 이 웹캐스트의 아카이브 다시보기는 회의 후 60일간 회사 웹사이트에서 이용 가능합니다.
Supernus Pharmaceuticals (Nasdaq: SUPN), une entreprise biopharmaceutique spécialisée dans les maladies du système nerveux central (CNS), a annoncé sa participation au 4ème Sommet Annuel sur les Nouveaux Mécanismes en Neuropsychiatrie de TD Cowen. Le président et PDG de l'entreprise, Jack Khattar, participera à un chat informel virtuel le jeudi 26 septembre 2024, à 8h40 ET.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via un lien fourni ou en visitant la section Événements & Présentations dans la zone des Relations Investisseurs du site web de l'entreprise à www.supernus.com. Une retransmission archivée du webinaire restera disponible sur le site de l'entreprise pendant 60 jours suivant la conférence.
Supernus Pharmaceuticals (Nasdaq: SUPN), ein biopharmazeutisches Unternehmen, das sich auf Erkrankungen des zentralen Nervensystems (CNS) spezialisiert hat, hat seine Teilnahme am 4. Jahresgipfel über neue Mechanismen in der Neuropsychiatrie von TD Cowen bekannt gegeben. Der Präsident und CEO des Unternehmens, Jack Khattar, wird am Donnerstag, den 26. September 2024, um 8:40 Uhr ET, an einem virtuellen Gespräch teilnehmen.
Interessierte Parteien können über den bereitgestellten Link auf ein Live-Webcast der Präsentation zugreifen oder die Rubrik Veranstaltungen & Präsentationen im Bereich Investor Relations auf der Website des Unternehmens unter www.supernus.com besuchen. Eine archivierte Wiederholung des Webcasts wird bis 60 Tage nach der Konferenz auf der Website des Unternehmens verfügbar sein.
- None.
- None.
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate virtually in a fireside chat at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit on Thursday, September 26, 2024, at 8:40 a.m. ET.
A live webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in PD, cervical dystonia, chronic sialorrhea and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates, including SPN-830; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACT:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com
FAQ
When is Supernus Pharmaceuticals (SUPN) participating in the TD Cowen Neuropsychiatry Summit?
Who will represent Supernus Pharmaceuticals (SUPN) at the TD Cowen Neuropsychiatry Summit?
How can investors access Supernus Pharmaceuticals' (SUPN) presentation at the TD Cowen Summit?
How long will the replay of Supernus Pharmaceuticals' (SUPN) presentation be available?
What is the focus of Supernus Pharmaceuticals (SUPN) as a biopharmaceutical company?
